Drug: omalizumab Quarter: 2016Q3
Total Records: 175 Number of Pages: 9
| DRUGNAME | PT | EventCount |
|---|---|---|
| Omalizumab | Gastrooesophageal reflux disease | 2 |
| OMALIZUMAB | Hypereosinophilic syndrome | 2 |
| Omalizumab | Hypertensive crisis | 2 |
| Omalizumab | Inguinal hernia | 2 |
| Omalizumab | Injection site cellulitis | 2 |
| Omalizumab | Injection site erythema | 2 |
| Omalizumab | Injection site induration | 2 |
| Omalizumab | Injection site pain | 2 |
| Omalizumab | Injection site warmth | 2 |
| Omalizumab | Jaundice neonatal | 2 |
| OMALIZUMAB | Myocarditis | 2 |
| Omalizumab | Natural killer cell count decreased | 2 |
| Omalizumab | Penis disorder | 2 |
| Omalizumab | Peptic ulcer | 2 |
| OMALIZUMAB | Pulmonary function test decreased | 2 |
| Omalizumab | Purulent discharge | 2 |
| Omalizumab | Tooth injury | 2 |
| Omalizumab | Umbilical granuloma | 2 |
| Omalizumab | Urticaria chronic | 2 |
| Omalizumab | Viral infection | 2 |
Total Records: 175 Number of Pages: 9